Iovision (Iohexol)

Iohexol contains iodine atoms that strongly absorb X‑ray photons. When injected, it circulates in the vascular and extracellular spaces, raising the X‑ray attenuation of blood and tissues. This creates a contrast between structures, allowing radiologists to differentiate vessels, organs, and lesions more distinctly on imaging studies.

The dose of Iovision is determined by the prescribing clinician based on the specific imaging procedure, patient size, and clinical indication. Healthcare professionals calculate the appropriate volume and concentration to achieve optimal contrast enhancement while minimizing risk.

The safety of Iovision in pregnancy or lactation has not been fully established. It should only be used if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and the decision must be made by the treating physician after careful consideration.

To order Iovision, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details, and any required import documentation.

Iovision (Iohexol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a lower incidence of adverse reactions compared with older high‑osmolality ionic agents. Its safety profile and imaging efficacy make it a preferred choice for many vascular and CT procedures, though selection depends on specific clinical needs.

Iovision should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Ensure the container is sealed tightly to maintain sterility and prevent contamination.

Iovision is administered by a qualified healthcare professional via intra‑arterial, intrathecal, or intravenous injection, depending on the imaging study. The injection is performed under controlled conditions, often using a power injector to deliver a precise volume and rate for optimal contrast enhancement.

Serious risks include severe allergic reactions such as anaphylaxis, acute renal failure, persistent hypotension, and cardiac arrhythmias. Patients with known iodine allergy, impaired kidney function, or uncontrolled thyroid disease are at higher risk and require careful assessment before administration.

Iovision should be avoided in patients with a documented severe allergy to iodinated contrast media, uncontrolled hyperthyroidism, severe renal impairment (eGFR < 30 mL/min/1.73 m²), or in those who have experienced a prior severe adverse reaction to a similar agent. Clinical judgment is essential for each case.